Skip to main content

Table 6 Summary of plasma Aβx-40 pharmacokinetic parameters

From: First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

Parameters (units)

Placebo (N = 19)

0.5 mg/kg (N = 6)

1 mg/kg (N = 5)

2 mg/kg (N = 14)

4 mg/kg (N = 16)

8 mg/kg (N = 22)

Cmax (ng/ml)

0.3511 (25)

3.321 (50)

6.959 (29)

8.202 (19)

11.89 (10)

18.03 (19)

Tmax (hours)

168 (0.00, 2540)

24.2 (22.3, 149)

24.0 (24.0, 169)

24.0 (24.0, 170)

166 (24.0, 238)

164 (92.2, 2050)

AUC0-13weeks (ng/hour/ml)

631.6 (23.3)

2647 (31)

6057 (47)

7854 (19)

12,940 (17)

22,820 (25)

t1/2 (days)

Not Reported

26.57*

32.14*

30.71 ± 3.23

25.4, 33.5*

Not reported

  1. N: Number of patients with pharmacokinetic parameters on Day1 (may be different from number of patients with estimable t1/2. Geometric mean (geometric %CV) for all except median (range) for Tmax and arithmetic mean ± standard deviation for t1/2. *Individual values for n < 3. AUC 0-13weeks Total area under the concentration–time curve to 13 weeks, C max Observed peak concentration, t 1/2 Apparent terminal phase elimination half-life, T max Time to peak concentration
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193